CASE REPORT article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1610783
This article is part of the Research TopicEvidence-Based Implementation of Innovations in Gynecological OncologyView all articles
Long-Term Survival in a Male with Müllerian Adenocarcinoma of the Pelvis: A 15-Year Case Report
Provisionally accepted- 1Oncology Departement, Integrated Oncology Unit, John Paul II Cancer institution Foundation (IRCCS), Bari, Italy
- 2Surgery Departement, Oncological Urology Operating Unit, John Paul II Cancer Institute Foundation (IRCCS), Bari, Italy
- 3Nuclear Medicine Unit, M.I.D., University of Bari Aldo Moro, Bari, Italy
- 4Pathological Anathomy Unit, John Paul II Cancer Institution Foundation (IRCCS), Bari, Italy
- 5Science of Health Departement, Digestive Surgery Unit, Magna Grecia University, Catanzaro, Italy
- 6Oncology Unit, IRCCS Saverio De Bellis, Castellana Grotte, Italy
- 7Surgical Departement, Anaesthesia, Resuscitation and Postoperative Intensive Care Unit, John Paul II Cancer Institute Foundation (IRCCS), Bari, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background. Müllerian adenocarcinoma is a very rare and aggressive cancer originating from the uterus and ovary, affecting almost exclusively women. Few cases of extragenital Müllerian adenocarcinomas have been reported, in various locations ranging from pelvic peritoneum to diaphragm peritoneum. Very few cases of Müllerian adenocarcinoma in males have been reported in scientific literature, usually localized in the prostate seminal vesicles and testicles, associated to a very poor prognosis.Case Summary. In this paper, we describe the unique clinical case of a man affected by advanced Müllerian adenocarcinoma on the left side of the pelvis, treated with combination of surgery plus chemotherapies plus radiotherapy and with a long follow-up. Patient survival was exceptional (almost 15 years from diagnosis) and the patient experienced a good quality of life during the numerous treatments. To the best of our knowledge, this is the first case report regarding a Müllerian adenocarcinoma of the pelvis in a man treated with a multimodal therapy approach and with a so long follow-up and very long survival. In consideration of the embryological origin of ovaries from Müllerian ducts and the absence of specific guidelines for standard treatment for this tumor, the patient was treated as if he had ovarian cancer, with optimal results.Conclusions. The management of this patient with the modern available lines of chemotherapy classically employed in ovarian cancer, plus radiotherapy combined with several cytoreductive surgery times could explain this long survival.
Keywords: Müllerian Adenocarcinoma in male, Pelvis, multimodal oncology therapy, Long survival, case report
Received: 12 Apr 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Ranieri, Porcelli, Mastrorosa, Di Palo, Ferrari, Zito, Ammendola, Laface, Mastrandrea and Berardone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Giovanni Mastrandrea, Surgical Departement, Anaesthesia, Resuscitation and Postoperative Intensive Care Unit, John Paul II Cancer Institute Foundation (IRCCS), Bari, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.